U.S. Building Stock News

Roper Technologies (ROP) is back in focus after its 2025 10-K highlighted strong growth tied to software and technology enabled products, supported by nine acquisitions, including CentralReach and Subsplash. See our latest analysis for Roper Technologies. At a share price of US$352.15, Roper’s short term momentum has picked up with a 1 week share price return of 6.1% after its 2025 10 K and recent dividend affirmation. However, this follows a 90 day share price return decline of 21.1% and a 1...

Science Applications International (SAIC) has just secured a new US$95 million contract with the U.S. Government Accountability Office to modernize the Technical Information Services program, putting its federal IT capabilities in sharper focus for investors. See our latest analysis for Science Applications International. The contract news arrives after a volatile stretch, with the 1-day share price return of 5.66% contrasting with a 30-day share price return decline of 11.57% and a 1-year...

Southern Copper recently reported slightly lower 2025 copper production and trimmed its 2026 outlook due to lower ore grades at Peruvian operations, while outlining nearly US$19.90 billion of long-term growth projects aimed at lifting annual output by 2035. At the same time, the company has kept earnings momentum intact, with consistent estimate beats and strong technical strength suggesting ongoing institutional interest despite nearer-term operational constraints. Now we’ll examine how...

The Trump administration’s new global tariffs pushed trade policy back into focus this week, coinciding with Booz Allen Hamilton Holding (BAH) working through civil revenue pressure, its worst public market drawdown, and steadier defense and national security demand. See our latest analysis for Booz Allen Hamilton Holding. Recent events, from contract cancellations after a major data breach to the latest tariff headlines and civil revenue pressure, have contributed to a 1 year total...

Moderna (MRNA) is back in the regulatory spotlight after the FDA reversed an earlier refusal and agreed to review its mRNA seasonal flu vaccine, while European regulators backed its combined flu and COVID-19 shot. See our latest analysis for Moderna. That regulatory reset has come alongside strong share price momentum, with a 13.77% 1 month share price return, a 99.04% 3 month share price return and a 67.56% year to date share price return at a last close of US$51.71. However, the 3 year...

Wondering whether Inter & Co at around US$8.89 still offers value or if most of the opportunity is already priced in? This article focuses on what the numbers say about that question. The stock has had mixed recent moves, with a 1.7% decline over the last 7 days and a 10.9% decline over the last 30 days, yet it still sits on a 5.2% year to date return and a 69.5% return over the past year, alongside a very large 3 year return of roughly 4x. Recent coverage around Inter & Co has centered on...

Recent performance and what it might signal Dorchester Minerals (DMLP) has drawn fresh attention after recent price moves, with the unit price around $25.50 and mixed returns across different periods, including gains over the past 3 months but a 1 year total return decline. See our latest analysis for Dorchester Minerals. At a share price of about $25.50, Dorchester Minerals has recently seen a 16.2% 90 day share price return, while the 1 year total shareholder return shows an 8.8% decline...

Warner Bros. Discovery overview and recent stock context Warner Bros. Discovery (WBD) continues to attract investor attention as its share price sits at $28.80, with recent returns of 0.2% over the past 3 months and 1.51x over the past year. See our latest analysis for Warner Bros. Discovery. With the share price at $28.80, Warner Bros. Discovery has logged a 20% 90 day share price return and a very large 1 year total shareholder return, which suggests momentum has been building as investors...

Healthpeak Properties has advanced its plan to spin out its senior housing portfolio via the Janus Living IPO, filing a preliminary prospectus for class A-1 shares that are expected to list on the NYSE under the ticker JAN. The move, alongside CEO Scott Brinker's recent presentation at the Citi 2026 Global Property CEO Conference, highlights how Healthpeak is reshaping its portfolio focus and communicating its long-term vision to investors. Next, we'll examine how the planned Janus Living...

In February 2026, Baker Hughes announced it would supply 25 BRUSH Power Generation electric generators, Automatic Voltage Regulators and cubicles to Boom Supersonic, expanding a prior 2025 agreement to support 1.3 GW of onsite power capacity for AI-focused data centers through deliveries scheduled from mid-2026 to 2028. This contract underscores Baker Hughes’ push into higher-value Industrial & Energy Technology solutions, tying its generator portfolio directly to the fast-growing AI data...

Earlier this week, Coinbase Global launched U.S. stock and ETF trading for millions of users, allowing zero-commission, 24/5 access to thousands of equities alongside cryptocurrencies and integrating one-click trading through a new partnership with Yahoo Finance. This move advances Coinbase’s aim to become an “Everything Exchange,” potentially deepening user engagement by unifying traditional and digital assets within a single platform and data ecosystem. We’ll now examine how Coinbase’s...

Veracyte FY 2025 Earnings Snapshot Veracyte (VCYT) has wrapped up FY 2025 with fourth quarter revenue of US$140.6 million and basic EPS of US$0.52, alongside net income of US$41.1 million, putting a clear spotlight on its profitability profile. The company has seen revenue move from US$118.6 million in Q4 2024 to US$140.6 million in Q4 2025, while basic EPS shifted from US$0.07 to US$0.52 over the same period, feeding into trailing twelve month EPS of US$0.84 on revenue of US$517.1 million...

Array Technologies (ARRY) has just wrapped up FY 2025 with Q4 revenue of US$226.0 million and a basic EPS loss of US$1.06, alongside trailing twelve month revenue of about US$1.3 billion and a TTM basic EPS loss of US$0.73. The company has seen quarterly revenue range from US$231.4 million in Q3 2024 to US$393.5 million in Q3 2025, while basic EPS has swung between a loss of US$1.02 in Q3 2024 and a profit of US$0.19 in Q2 2025. This sets up a story where investors are watching how...

Antero Resources (NYSE:AR) has completed the sale of substantially all of its Utica Shale oil and gas assets. The company is using the proceeds to redeem a significant portion of its outstanding senior notes and reduce debt. The transaction marks a major shift in Antero's portfolio and balance sheet structure. Antero Resources, trading at $34.38, has seen mixed share performance, with a 1.9% decline over the past week, flat returns over 30 days, and a 0.5% gain year to date. Over longer...

Fastenal (NasdaqGS:FAST) reported a 59% year over year increase in CEO Daniel L. Florness's compensation in a new SEC filing. Multiple insiders have purchased Fastenal stock over the past six months. The company has been awarded nearly $8 million in government contracts over the last year. Fastenal, trading at around $45.68 per share, has seen its stock return 13.0% year to date and 25.9% over the past year, with longer term gains of 85.9% over three years and 133.3% over five years. In...

Intellia Therapeutics (NTLA) closed FY 2025 with Q4 revenue of US$23.0 million and a basic EPS loss of US$0.83, as the company continued to invest heavily in its gene editing pipeline. Over the last six quarters, revenue has moved from US$9.1 million in Q3 2024 to US$23.0 million in Q4 2025, while quarterly basic EPS losses have ranged between US$0.83 and US$1.34. This has left margins firmly in loss-making territory even as the top line scaled up. See our full analysis for Intellia...

Earlier in February 2026, Fitch Ratings affirmed Ally Financial’s Long-Term Issuer Default Rating at BBB- while revising its outlook to Positive, reflecting the rating agency’s view of improving profitability, credit performance, and capital strength following Ally’s sharpened focus on auto and corporate lending. By selling its personal loans and card portfolios and allowing its mortgage book to run off, Ally is concentrating on core lending businesses in a way that rating agencies now view...

Palo Alto Networks agreed to acquire CyberArk and Koi Security to deepen its AI security platform. The company expanded its Nvidia integration and launched Unit 42 Managed XSIAM 2.0 to push further into AI driven cybersecurity. These moves signal a shift toward platform consolidation that could affect profitability and integration complexity in the near term. Palo Alto Networks (NasdaqGS:PANW) is making an aggressive push into AI centered cybersecurity as its share price sits at $149.4. The...

Revolve Group (RVLV) has attracted fresh attention after recent trading action left the stock with mixed short term performance, including a decline over the past month alongside gains over the past 3 months and the past year. See our latest analysis for Revolve Group. At a share price of $26.30, Revolve Group’s recent 1 day share price return of 7.96% and 7 day share price return of 4.91% contrast with a 30 day share price return of 9.50% and a flat 1 year total shareholder return of 0.19%...

If you are wondering whether Macy's at around US$20.35 is priced attractively or not, this article will walk you through what the current market price might be implying about its value. The stock has seen mixed recent performance, with a 7.5% decline over the last 7 days and a 0.1% decline over 30 days, while still showing a 51.7% return over 1 year and a 59.9% return over 5 years. Recent headlines around Macy's have focused on the long running discussion about the future of department...

Citi recently placed KLA Corp on a 30‑day positive Catalyst Watch ahead of its 12 March Investor Day in New York, citing expectations for a stronger long‑term financial model and potential product announcements. This fresh attention comes as KLA benefits from accelerating demand for advanced packaging and inspection tools tied to AI and leading‑edge chip production. We'll now examine how Citi's Catalyst Watch and expectations for KLA's Investor Day may influence the company's existing...

Ingredion (INGR) is back on investors’ radar after appointing Univar Solutions as the exclusive distributor for its pharmaceutical starches in the United States and Canada, expanding access to its excipient portfolio across pharmaceutical and nutraceutical customers. See our latest analysis for Ingredion. The Univar agreement arrives after a steady build in recent momentum, with Ingredion’s 90 day share price return of 8.93% and year to date share price return of 6.69%, even as the 1 year...

In February 2026, Visteon Corporation reported fourth-quarter and full-year 2025 results showing softer net income and earnings per share alongside slightly lower annual sales of US$3.77 billion, while its Board raised the quarterly dividend to US$0.375 per share payable on March 16, 2026, and confirmed 2026 sales guidance of US$3.63 billion to US$3.83 billion. At the same time, Visteon completed a US$225.93 million share repurchase program that retired about 7.17% of its shares, signaling a...

Marriott International (NasdaqGS:MAR) has secured more than 100 new hotel deals in India, marking record expansion milestones in South Asia. The company reports a strong development pipeline in the wider Asia Pacific region, including targeted growth in Vietnam. Marriott has reopened the JW Marriott Atlanta Downtown after a major renovation, adding fresh capacity to its luxury portfolio in the United States. Marriott International, known for its global hotel and lodging brands, is leaning...